3366. ASO Author Reflections: What is the Optimal Method for
Predicting a Response to Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic
Cancer?
Yun WG, Jang JY.
Ann Surg Oncol. 2024 Feb;31(2):1364-1365. doi:
10.1245/s10434-023-14658-y.Link
3365. Response to "The role of adjuvant chemotherapy in
management of stage I pancreatic ductal adenocarcinoma deserves independent high
quality research".
3362. Clinical
outcomes of minimally invasive (laparoscopic and robotic) versus open extended
cholecystectomy: A multicenter propensity score matched study.
Sohn HJ, Lee M, Han Y, Kwon W, Yoon YS, Han HS, Lim CS, Jang JY.
J Hepatobiliary Pancreat Sci. 2024 Feb 7. doi: 10.1002/jhbp.1419.Link
3361. Systematic review on surveillance for non-resected branch-duct intraductal
papillary mucinous neoplasms of the pancreas.
Kazmi SZ, Jung HS, Han Y, Yun WG, Cho YJ, Lee M, Kwon W, Castillo CF, Del
Chiaro M, Marchegiani G, Goh BKP, Hijioka S, Majumder S, Nakai Y, Shin A, Jang
JY.
3360. CORRIGENDUM:
Correction of the ethical statements. Training efficacy of robotic duct-to-
mucosa pancreaticojejunostomy simulation using silicone models for surgical
fellows.
Lee M, Han Y, Kang JS, Choi YJ, Sohn HJ, Kwon W, Jang JY.
Ann Surg Treat Res. 2024 Apr;106(4):241. doi:
10.4174/astr.2024.106.4.241.Link
3359. Re-evaluation of risk and oncological outcomes of resection of veins and
arteries in the resection of pancreatic cancer.
Lee M, Chae YS, Park S, Yun WG, Jung HS, Han Y, Kwon W, Park JS, Jang JY.
3358. Emerging role of local
treatment in the era of advanced systemic treatment in pancreatic cancer with
liver metastasis: A systematic review and meta-analysis.